Strategic partnerships Debiopharm acts as a bridge by identifying high potential in licensing assets, overseeing clinical development, and then out licensing to large pharma to maximize patient access. This model offers opportunities for universities and biotech startups with promising oncology or bacterial infection molecules to partner for development and global commercialization.

Global expansion The company pursues geographic and regulatory growth, including launching IDEAL Japan to support academic researchers and collaborating on novel gonorrhea therapies with GARDP. This creates openings for regional co development, joint funding, and market entry partnerships in Japan and other regions.

AI and biomarkers Debiopharm is advancing AI and biomarker capabilities through investments in ViewsML and alliance with NetTargets to combine AI with MLINK for next generation ADCs. This points to opportunities for biomarker driven trials, companion diagnostics, and data driven patient selection collaborations that de risk programs.

Oncology ADCs With a focus on oncology and developing conjugation enabled radiopharmaceuticals and dual payload ADCs, Debiopharm is well positioned to partner with imaging, radiopharma, and ADC developers to co create next generation cancer therapies and accelerate trials.

Deployment readiness As a mid sized Swiss pharma with a track record of licensing assets like Triptorelin and Oxaliplatin and a modern tech stack including Veeva eTMF, Salesforce Engage, and DocuSign, Debiopharm demonstrates strong collaboration processes and openness to early stage partnerships.